Shire subsidiary Shire Laboratories filed suit in the U.S. against Teva Pharmaceutical Industries, claiming Teva's plan to sell a generic version of the attention deficit hyperactivity disorder drug Adderall XR infringes on Shire's patent. The drug, which is Shire's major product, accounted for 26% of the ADHD market last year.

Full Story:
Red Herring

Related Summaries